-
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 12:30 GMT
… the trial. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, … has shown that omecamtiv mecarbil increases cardiac contractility … omecamtiv mecarbil, demonstrated a statistically significant effect of treatment with omecamtiv mecarbil …
-
Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies | DelveInsight
23 Jan 2025 01:21 GMT
… in the pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide … Therapies and Key Companies
Omecamtiv Mecarbil: Cytokinetics
KERENDIA (finerenone … Pipeline Chronic Heart Failure Therapies
Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide …
-
Congestive Heart Failure Market Predicted to See Upsurge Through 2034, Highlights DelveInsight
21 Jan 2025 19:40 GMT
… COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure … Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with symptomatic … and severely reduced ejection fraction. Omecamtiv mecarbil is a novel investigational selective …
-
Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: Withdrawn application
31 May 2024 14:36 GMT
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …
-
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
21 Jan 2025 12:30 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Heart failure with Reduced Ejection Fraction Market to Expand Significantly by 2032, States DelveInsight Report
20 Jan 2025 21:10 GMT
… 3 confirmatory trial evaluating omecamtiv mecarbil in patients with … severely reduced ejection fraction. Omecamtiv mecarbil, a novel investigational selective … AGT-LRx: Ionis Pharmaceuticals
• Omecamtiv mecarbil: Cytokinetics
Scope of the Heart …
-
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
13 Jan 2025 12:30 GMT
… obstructive HCM, in 2H 2025.
Omecamtiv mecarbil (cardiac myosin activator) Continue … confirmatory Phase 3 clinical of omecamtiv mecarbil in patients with symptomatic … HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, …
-
FDA Declines Approval for Omecamtiv Mecarbil in HFrEF
01 Mar 2023 20:08 GMT
… advisers recommended against approval of omecamtiv mecarbil for chronic HFrEF, as reported … by theheart.org | Medscape Cardiology, omecamtiv mecarbil produced a positive result for … an additional clinical trial of omecamtiv mecarbil are required to establish …
-
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
28 Feb 2023 22:31 GMT
… Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, … access the call. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, selective, … research has shown that omecamtiv mecarbil increases cardiac contractility without …
-
FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure
14 Dec 2022 21:19 GMT
… has recommended against approval of omecamtiv mecarbil (Cytokinetics) for the treatment of … reduced ejection fraction (HFrEF).
Omecamtiv mecarbil is a first-in-class … by theheart.org | Medscape Cardiology, omecamtiv mecarbil produced a positive result for …
About
© 1995-2025